SOLID TARGET TECHNOLOGY FOR MEDICAL CYCLOTRONS

    Solid Target Manufacturing


    Solid targetry for Tc-99m, Ga-68 and Cu-64 isotope production


     

    Solid Target Transportation


    Reliable and compact pneumatic transfer system for solid targets


    Isotope Separation Systems


    Dissolution and purification processes to extract isotopes for diagnostic imaging


    INNOVATION EXCELLENCE

    ARTMS™ Products is a leader in the development of novel technologies which enable the production of the world’s most-used diagnostic imaging isotopes. Our flagship product is the QUANTM99, a hardware and consumable system for producing Tc-99m on medical cyclotrons to enable cost-effective, decentralized, and local production of medical isotopes.

    MEDICAL ISOTOPE PRODUCTION
    NUCLEAR CHEMISTRY
    QUALITY ANALYTICS
    REGULATORY COMPLIANCE
    INDUSTRY ENGAGEMENT

    BREAKTHROUGH TECHNOLOGY

    In 2007 & 2009 the world experienced shortages due to reactor outages, highlighting the vulnerability of the current supply chain. The shortages caused in significant price increases, delayed and canceled medical procedures and resulted in a decrease in patient care. In response, ARTMS Products Inc. developed an award-winning, first-to-market, locally deployable method for producing Tc-99m using existing, hospital-based medical cyclotrons. ARTMS holds the exclusive global commercialization rights to the award-winning and proprietary Canadian technology that addresses these challenges and offers the prospect of revolutionizing the nuclear medicine industry.

    EXISITING SUPPLY

    ARTMS PHILOSOPHY

    IN THE NEWS

    Researchers at the BC Cancer Agency in Vancouver and TRIUMF, the Canadian national particle and nuclear physics lab, have successfully produced vital supplies of Technetium-99m, a medical imaging isotope, using a retrofitted cyclotron, a type of particle accelerator already in […]

    A Canadian-led team says that it has succeeded in proving the feasibility of using particle accelerators instead of nuclear reactors to produce a badly needed medical isotope. If health regulators approve the method, it will place supplies of the crucial […]

    The first commercial shipment of medical isotopes produced using a new particle-accelerator-based technique has been made by scientists at the Canadian Light Source (CLS). Molybdenum-99 (Mo-99) decays to create technetium-99m (Tc-99m), which is used to tag radiopharmaceuticals and plays a […]

    See all our news

    AWARD WINNING LEADERSHIP

    Dr. Kaley Wilson, CEO

    Dr. Kaley Wilson is CEO of ARTMS Products. Kaley is also currently…

    Dr. Paul Schaffer, CTO

    Dr. Paul Schaffer is CTO of ARTMS Products and Head of TRIUMF's…

    The prestigious NSERC Brockhouse Canada Prize was awarded in recognition of the outstanding interdisciplinary research involved in developing ARTMS medical isotope imaging technologies. The annual Prize was presented by His Excellency the Right Honourable David Johnston, the 28th Governor General of Canada.

    PARTNERS

    inline-flex